Washington life science companies brought in about $5.08B in total investment last year, according to Life Science Washington’s first-annual 2021 Washington State Investor Report.
Over 180 investors participated in 112 life sciences deals ranging from venture capital, public offerings, mergers and acquisitions, and reverse mergers. Amgen’s purchase of Seattle-based Rodeo Therapeutics for $55M with $666M in potential milestone payments was the largest single deal in 2021, according to the report.
In all, mergers and acquisitions accounted for $1.8B of the total investment, followed by initial public offerings for $1.1B and early-stage venture capital for $889M, while later-stage venture capital contributed $849M.